MTI-GlobalStem, a provider of optimized transfection reagents and protocols for human induced pluripotent stem (iPS) cells and other cells that are difficult to transfect, announces its launch of the PluriQ™ G9™ Gene Editing System and PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete system for culturing and transfecting human pluripotent stem cells for gene editing. The system includes the G9™ Maintenance Medium and G9™ VTN Recombinant (vitronectin) plate coating for culturing human induced pluripotent (iPS) or embryonic stem (hES) cells in a manner that maximizes transfection of genome editing constructs by the included EditPro™ Stem Transfection Reagent. EditPro™ Stem is optimized for delivery of CRISPR/Cas9 editing via DNA Cas9 vectors, Cas9 mRNA with double-stranded DNA (G-block), Cas9 mRNA with tracr/guide RNA, or Cas9 protein with tracr/guideRNA. It is effective for delivery of TALEN and ZFN editing tools as well giving the researcher total flexibility in experimental design. With such high efficiency delivery, up to 90%, it is not necessary to include an antibiotic selection in the editing design. PluriQ™ G9™ Cloning Medium supports single cell/well clonal selection for human iPS or human ES cell lines. This technical achievement overcomes human pluripotent stem cells’ propensity to die or differentiate when plated as single cells, and enables scientists to readily create clonal, genetically modified lines for their experiments.